The FDA has approved Afrezza, an ultra rapid-acting inhaled insulin, for children and adolescents aged 6 and older with type 1 and type 2 diabetes. This marks the first inhaled mealtime insulin option for pediatric patients, offering a needle-free alternative that can be taken at the start of meals, providing flexibility for managing diabetes during daily activities like school and sports. The approval is based on extensive clinical trials and over 20 years of development using MannKind's Technosphere technology. Afrezza is now available for eligible patients at $35 or less per month with support from MannKind Cares.
ZetaChain introduced Anuma, its first consumer AI product that offers a private, encrypted memory layer allowing users to maintain their context across various AI models like ChatGPT, Claude, and Gemini. Powered by the ZETA token, Anuma enables users...
Proficient Auto Logistics announced its participation in the William Blair Growth Stock Conference on June 2, 2026, where its CEO and CFO will meet with investors. The company will report its second quarter 2026 financial results on August 10, 2026, ...
Constellation Software Inc. has finalized its acquisition of a majority interest in Derbysoft Holdings Limited through its Juniper Group operating unit. DerbySoft, which includes PKFARE, will continue to operate independently under CEO Ted Zhang. Thi...
Hewlett Packard Enterprise (HPE) shares soared 36.4% after hours following a strong Q2 report that beat earnings and revenue estimates, driven by robust demand for AI infrastructure and expanded networking products. CEO Antonio Neri highlighted recor...
Silver Point Capital has co-led a $200 million secured term loan financing for Liberty Puerto Rico subsidiaries to support their liquidity needs. The loan has a fixed interest rate of 12% per annum and matures in 2030. Of the total facility, $150 mil...
